{"hq_id":"hq-c-org-000520","name":"Povidone (PVP, K30)","context":"human_adult","timestamp":"2026-05-01T19:45:55.948Z","risk_level":"low","risk_profile":{"magnitude":{"mean":0.2,"weightedMean":0.2,"std_dev":0,"confidence_interval_95":[0.2,0.2],"source_positions":[{"source":"HQ_DIRECT","year":2026,"value":0.2,"weight":0.35}]},"confidence":{"mean":0.5,"weightedMean":0.5,"std_dev":0,"confidence_interval_95":[0.5,0.5],"source_positions":[{"source":"HQ_DIRECT","year":2026,"value":0.5,"weight":0.35}]},"recency":{"mean":1,"weightedMean":1,"std_dev":0,"confidence_interval_95":[1,1],"source_positions":[{"source":"HQ_DIRECT","year":2026,"value":1,"weight":0.35}]},"methodology":{"mean":0.7,"weightedMean":0.7,"std_dev":0,"confidence_interval_95":[0.7,0.7],"source_positions":[{"source":"HQ_DIRECT","year":2026,"value":0.7,"weight":0.35}]},"specificity":{"mean":0.92,"weightedMean":0.92,"std_dev":0,"confidence_interval_95":[0.92,0.92],"source_positions":[{"source":"HQ_DIRECT","year":2026,"value":0.92,"weight":0.35}]},"consensus":{"exists":false,"strength":0,"disagreement_magnitude":0,"warning":"single_source_warning"}},"interpretation":{"summary":"Single source (HQ_DIRECT, 2026) indicates low risk.","confidence_note":"Evidence quality varies; interpretation requires caution.","context_note":null,"warning":"single_source_warning"},"sources":[],"warnings":["unmapped_classification:US FDA / EFSA (Povidone — polyvinylpyrrolidone; PVP — FDA-approved pharmaceutical excipient (inactive ingredient database; oral, topical, parenteral routes); EFSA ADI 50 mg/kg bw/day for povidone (E1201); no carcinogenicity classification by IARC, NTP, US EPA, or EFSA for the polymer; residual monomer N-vinylpyrrolidone (NVP) is a process impurity controlled by ICH Q3B limits — NVP itself classified as possibly genotoxic; tissue accumulation with high-dose parenteral administration documented historically (thesaurismosis); povidone-iodine complex (Betadine) is a separate antimicrobial compound with different safety profile):no carcinogenicity classification for pvp polymer;","unmapped_classification:EPA CTX / IARC:group 3 - not classifiable as to its carcinogenici","unmapped_classification:EPA CTX / Genetox:genotoxicity: positive (ames: positive, 4 positive","unmapped_classification:EPA CTX / Genetox:genotoxicity: positive (ames: positive, 4 positive","single_source_warning"],"meta":{"synthesis_version":"1.0.0","config_version":"1.0.0","n_sources":1,"db_version":25,"warnings":["unmapped_classification:US FDA / EFSA (Povidone — polyvinylpyrrolidone; PVP — FDA-approved pharmaceutical excipient (inactive ingredient database; oral, topical, parenteral routes); EFSA ADI 50 mg/kg bw/day for povidone (E1201); no carcinogenicity classification by IARC, NTP, US EPA, or EFSA for the polymer; residual monomer N-vinylpyrrolidone (NVP) is a process impurity controlled by ICH Q3B limits — NVP itself classified as possibly genotoxic; tissue accumulation with high-dose parenteral administration documented historically (thesaurismosis); povidone-iodine complex (Betadine) is a separate antimicrobial compound with different safety profile):no carcinogenicity classification for pvp polymer;","unmapped_classification:EPA CTX / IARC:group 3 - not classifiable as to its carcinogenici","unmapped_classification:EPA CTX / Genetox:genotoxicity: positive (ames: positive, 4 positive","unmapped_classification:EPA CTX / Genetox:genotoxicity: positive (ames: positive, 4 positive"]},"schema":"synthesis"}